Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Specimen Handling 21Biopsy 15Magnetic Resonance Spectroscopy 12Cyclophosphamide 4decitabine and cedazuridine drug combination 3X-Rays 3Vincristine 3Nivolumab 3Doxorubicin 3venetoclax 2trastuzumab deruxtecan 2olaparib 2iadademstat 2Taxes 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Prednisone 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cetuximab 2CTLA-4 Antigen 2Azacitidine 2Actinium 2(225)Ac-DOTA-c(RGDyK) 2sargramostim 1relatlimab 1prednylidene 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × NIH × Biological Assay × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡